• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Multiple sclerosis - Articles and news items

progression-ms

Novartis’ long term RRMS drug limits disease progression

Industry news / 16 September 2016 / Niamh Louise Marriott, Digital Content Producer

Gilenya impacts four key measures of disease activity: relapses, MRI lesions, brain shrinkage (brain volume loss) and disability progression…

patent-redhill-biopharma

RedHill Biopharma receives patent approval for MS drug

Industry news / 30 August 2016 / Niamh Louise Marriott, Digital Content Producer

A first Phase III study with RHB-104 for the treatment of Crohn’s disease is currently ongoing, as well as a Phase IIa proof-of-concept study for the treatment of MS…

SPMS endpoint novartis

Novartis’ phase III MS study successfully meets endpoints

Industry news / 25 August 2016 / Novartis

The study included 1,651 people with SPMS randomised to receive either 2mg BAF312 or placebo in a 2:1 ratio respectively, the primary endpoint being an improvement in the time to three-month confirmed disability progression, as measured by the expanded disability status scale (EDSS), versus placebo…

Myelin deterioration multiple sclerosis

Last patient visit in Phase IIa study with RHB-104 for multiple sclerosis

Industry news / 3 August 2016 / RedHill Biopharma Ltd.

The last patient visit has been completed in the Phase IIa study evaluating RHB-104 in patients treated for relapsing-remitting multiple sclerosis (RRMS)…

RedHill Biopharma has last patient visit in phase IIa study with RHB-104 for multiple sclerosis

RedHill Biopharma has positive results with RHB-104 for multiple sclerosis

Industry news / 1 August 2016 / RedHill Biopharma Ltd.

RHB-104 for relapsing-remitting multiple sclerosis show positive safety and efficacy signals after the 24-week treatment period …

zinbryta

EC grants marketing authorisation for Zinbryta in multiple sclerosis

Industry news / 5 July 2016 / Victoria White, Digital Content Producer

The approval of Zinbryta is supported by results from two studies, including DECIDE, the largest and longest head-to-head Phase III study ever conducted in MS…

Ocrevus

Ocrevus marketing applications under review by the EMA and FDA

Industry news / 28 June 2016 / Victoria White, Digital Content Producer

If approved by the EMA and FDA for both indications, Ocrevus would be the first and only treatment for both forms of multiple sclerosis…

ms

Replacing diseased immune system halts MS progression

Industry news / 10 June 2016 / Victoria White, Digital Content Producer

A study shows that completely wiping out the immune system and then regenerating a new one can eliminate all signs of damaging brain inflammation in MS…

opicinumab

Phase II study of opicinumab in MS misses primary endpoint

Industry news / 7 June 2016 / Victoria White, Digital Content Producer

The primary endpoint primary endpoint was a multicomponent measure evaluating improvement of physical function, cognitive function, and disability…

Daclizumab

Daclizumab demonstrates significant improvements in cognition in RRMS

Industry news / 22 April 2016 / Victoria White, Digital Content Producer

New data demonstrates daclizumab’s positive cognitive outcomes and safety profile in patients with relapsing-remitting multiple sclerosis (RRMS)…

Tecfidera

Tecfidera demonstrates sustained efficacy in RRMS studies

Industry news / 18 April 2016 / Victoria White, Digital Content Producer

Biogen has unveiled new Tecfidera research that reinforces its sustained efficacy in newly diagnosed relapsing-remitting multiple sclerosis patients…

RHB-104

Encouraging top-line interim results for RHB-104 in RRMS

Industry news / 5 April 2016 / Victoria White

RedHill has announced encouraging top-line interim results from its CEASE-MS study of RHB-104 in patients with relapsing-remitting multiple sclerosis…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +